The outcomes of atezolizumab therapy in combination with carboplatin and etoposide for small-cell lung cancer. PD-(L)1 inhibitors plus anlotinib: A superior option for second-line treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results